Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.50 |
| ▸ | PRNP | P04156 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.47 |
| ▸ | NCF1 | P14598 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2098479 | 0.81 | RXFP1 (0.53) | RXFP1PRNPKDM4ENPSR1ALDH1A1 | |
| SCHEMBL6899659 | 0.81 | RXFP1 (0.53) | RXFP1PRNPKDM4ENPSR1ALDH1A1 | |
| SCHEMBL10410970 | 0.77 | RXFP1 (0.50) | RXFP1PRNPKDM4ENPSR1ALDH1A1 | |
| SCHEMBL10411067 | 0.77 | RXFP1 (0.50) | RXFP1PRNPKDM4ENPSR1ALDH1A1 | |
| SCHEMBL5807877 | 0.77 | RXFP1 (0.51) | RXFP1PRNPKDM4ENPSR1ALDH1A1 | |
| SCHEMBL29979791 | 0.77 | CYP1A2 (0.58) | RXFP1PRNPKDM4ENPSR1ALDH1A1 | |
| SCHEMBL2200585 | 0.77 | NCF1 (0.52) | RXFP1PRNPKDM4ENPSR1ALDH1A1 | |
| SCHEMBL2817162 | 0.77 | CYP1A2 (0.58) | RXFP1PRNPKDM4ENPSR1ALDH1A1 | |
| SCHEMBL11326601 | 0.77 | RXFP1 (0.50) | RXFP1PRNPKDM4ENPSR1ALDH1A1 | |
| SCHEMBL7857102 | 0.76 | PRNP (0.49) | RXFP1PRNPKDM4ENPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4314324-A1 | BENIGN SCAR-FORMING CLEAVABLE LINKERS | Ultima Genomics, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2022212408-A1 | BENIGN SCAR-FORMING CLEAVABLE LINKERS | ULTIMA GENOMICS, INC. (US) | 2022-10-06 | — | — | WO | claimed |
| US-6989263-B1 | Method for identifying and using compounds that inactivate HIV-1 and other retroviruses by attacking highly conserved zinc fingers in the viral nucleocapsid protein | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-01-24 | — | — | US | claimed |
| US-20030198648-A1 | Methods for identifying compounds which inhibit binding of nucleocapsid 7 protein to HIV-1 RNA | ACHILION PHARMACEUTICALS | 2003-10-23 | — | — | US | claimed |
| WO-2003060098-A2 | METHODS FOR IDENTIFYING COMPOUNDS WHICH INHIBIT BINDING OF NUCLEOCAPSID 7 PROTEIN TO HIV-1 RNA | ACHILLION PHARMACEUTICALS, INC. (US) | 2003-07-24 | — | — | WO | claimed |
| EP-0782632-B1 | A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN | US GOV HEALTH & HUMAN SERV (US) | 2003-04-16 | — | — | EP | claimed |
| US-6001555-A | DISSOCIATING A ZINC FINGER BY CONTACTING THE PROTEIN WITH A DISULFIDE, A MALEIMIDE, AN ALPHA-HALOGENATED KETONE, A HYDRAZIDE, A NITRIC OXIDE OR DERIVATIVES, CUPRIC IONS, FERRIC IONS OR THEIR COMPLEXES; SYNERGISTIC EFFECTS WITH VIRICIDES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-12-14 | — | — | US | claimed |
| EP-0782632-A1 | A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary of the Department of Health and Human Services (US) | 1997-07-09 | — | — | EP | claimed |
| WO-1996009406-A9 | A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN | — | 1996-05-23 | — | — | WO | claimed |
| WO-1996009406-A1 | A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-03-28 | — | — | WO | claimed |
| US-20240132955-A1 | BENIGN SCAR-FORMING CLEAVABLE LINKERS | ULTIMA GENOMICS, INC. | 2024-04-25 | — | — | US | disclosed |
| EP-4314324-A1 | BENIGN SCAR-FORMING CLEAVABLE LINKERS | Ultima Genomics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022212408-A1 | BENIGN SCAR-FORMING CLEAVABLE LINKERS | ULTIMA GENOMICS, INC. (US) | 2022-10-06 | — | — | WO | disclosed |
| CN-104448700-B | Resin combination | 味之素株式会社 | 2019-01-22 | — | — | CN | disclosed |
| US-20160160178-A1 | IMMUNOTHERAPY USING STEM CELLS | WHITE OAK IND INC (US) | 2016-06-09 | — | — | US | disclosed |
| EP-0417057-B1 | Heterocyclic thiol-based sulfenimide compounds and rubber compositions containing them | MONSANTO CO (US) | 1995-03-01 | — | — | EP | disclosed |
| US-5260454-A | Cure accelerator for natural and synthetic rubber; imroved cure rate, longer scorch delay | MONSANTO COMPANY (US) | 1993-11-09 | — | — | US | disclosed |
| US-5189174-A | Rubber curing agent | MONSANTO COMPANY (US) | 1993-02-23 | — | — | US | disclosed |
| US-5079305-A | Improved cure rate, scorch delay and reversion resistance | MONSANTO COMPANY (US) | 1992-01-07 | — | — | US | disclosed |
| EP-0417057-A2 | Heterocyclic thiol-based sulfenimide compounds and rubber compositions containing them | MONSANTO COMPANY (US) | 1991-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160160178-A1 | IMMUNOTHERAPY USING STEM CELLS | CD14, ICOS, BMP4 | RXFP1 2083/4885PRNP 3393/4885KDM4E 562/4885 |
| US-20030198648-A1 | Methods for identifying compounds which inhibit binding of nucleocapsid 7 protein to HIV-1 RNA | MRPS27, SNRPE, NSUN2 | RXFP1 4374/4885PRNP 626/4885KDM4E 4292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.